Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
MedPlus Health Services Limited is primarily engaged in pharmaceuticals and diagnostic services across India. It operates a vast network of over 5,000 stores, making it the second-largest pharma retailer in the country.
The company added 500 stores in the past year, indicating its focus on scaling up operations and increasing market penetration. Its cluster-based expansion strategy emphasizes deepening reach in existing markets.
MedPlus reported a significant revenue increase to ₹18,061 million with a 26.2% gross margin, showcasing strong financial performance. The operating EBITDA for pharmacies stood at ₹925 million, maintaining steady growth margins.
The integration of a large private label range, both in pharma and non-pharma categories, is a key focus for MedPlus, aimed at enhancing margins and the overall share of wallet. This strategy includes developing its extensive product portfolio.
MedPlus demonstrates a clear commitment to omni-channel retailing, leveraging its vast store network to offer competitive services like rapid delivery and lower operational costs, setting it apart from pure online competitors.
Retailing
Pharmacy Retail
10,462 Cr
Low Risk
50.5
72.4
2.5
5.8
1,052.05
603.00
Sales CAGR
Profit CAGR
ROE
ROCE
Upcoming Result Date: May 19, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stock
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Medplus Health Services Ltd (MEDPLUS) is currently trading at 871.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
MedPlus Health Services Limited is primarily engaged in pharmaceuticals and diagnostic services across India. It operates a vast network of over 5,000 stores, making it the second-largest pharma retailer in the country. The company added 500 stores in the past year, indicating its focus on scaling up operations and increasing market penetration. Its cluster-based expansion strategy emphasizes deepening reach in existing markets. MedPlus reported a significant revenue increase to ₹18,061 million with a 26.2% gross margin, showcasing strong financial performance. The operating EBITDA for pharmacies stood at ₹925 million, maintaining steady growth margins. The integration of a large private label range, both in pharma and non-pharma categories, is a key focus for MedPlus, aimed at enhancing margins and the overall share of wallet. This strategy includes developing its extensive product portfolio. MedPlus demonstrates a clear commitment to omni-channel retailing, leveraging its vast store network to offer competitive services like rapid delivery and lower operational costs, setting it apart from pure online competitors.
Over the past 52 weeks, Medplus Health Services Ltd has traded between a low of ₹603.00 and a high of ₹1,052.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Medplus Health Services Ltd has a market capitalization of approximately 10,629.04. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Medplus Health Services Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 51.35 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 10,629.04 Cr, Medplus Health Services Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Medplus Health Services Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Medplus Health Services Ltd is 51.35. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
2
Neutral
7
Bullish
5
Bearish
17
Neutral
7
Bullish
22
Bearish
15
Neutral
0
Bullish
17
Board Meeting Results
MedPlus rescheduled its board meeting to May 20, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026; trading window closed Apr 1–May 22, 2026.
Board Meeting - Results
MedPlus rescheduled its Board meeting to May 20, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and FY ended March 31, 2026; trading window closed Apr 1–May 22, 2026.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2109.00 | 12,571 Cr | 26.48 | 5.24 | 1.43 | 19.78 | 20.54 | 10.26 | ||
224.05 | 12,477 Cr | -66.74 | 2.61 | 0.00 | -2.52 | -0.18 | -2.95 | ||
447.00 | 10,677 Cr | 26.50 | 6.99 | 1.82 | 26.38 | 26.96 | 16.36 | ||
834.75 | 10,629 Cr | 51.35 | 5.76 | 0.00 | 10.57 | 11.47 | 5.79 | ||
1746.35 | 9,217 Cr | 46.04 | 3.71 | 0.00 | 8.03 | 10.32 | 7.76 | ||
64.17 | 8,273 Cr | -12.84 | 1.32 | 0.00 | -11.85 | -2.46 | -3.91 | ||
194.50 | 7,856 Cr | 52.23 | 9.98 | 0.00 | 25.72 | 13.13 | 6.30 | ||
| Median: 7 Co. | — | 447.00 | 10,629 Cr | 26.50 | 5.24 | 0.00 | 10.57 | 11.47 | 6.30 |
